Switching to a second TNF inhibitor in inflammatory bowel disease may raise the risk for immune-mediated inflammatory ...

First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases ...

Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing multiple small-molecule programs for autoimmune, ...

For patients with higher-grade or progressive IDH -mutant glioma, how do you individualize choice between radiotherapy (RT) ...

The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) ...

VpCI Chameleon is a corrosion inhibitor that simplifies and improves the wet layup process for boilers whose steam may come ...

CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026Planned milestones include pivotal dose selection, ...

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and ...